Postmenopausal hormone replacement therapy: scientific review - PubMed (original) (raw)
Review
. 2002 Aug 21;288(7):872-81.
doi: 10.1001/jama.288.7.872.
Affiliations
- PMID: 12186605
- DOI: 10.1001/jama.288.7.872
Review
Postmenopausal hormone replacement therapy: scientific review
Heidi D Nelson et al. JAMA. 2002.
Abstract
Context: Although postmenopausal hormone replacement therapy (HRT) is widely used in the United States, new evidence about its benefits and harms requires reconsideration of its use for the primary prevention of chronic conditions.
Objective: To assess the benefits and harms of HRT for the primary prevention of cardiovascular disease, thromboembolism, osteoporosis, cancer, dementia, and cholecystitis by reviewing the literature, conducting meta-analyses, and calculating outcome rates.
Data sources: All relevant English-language studies were identified in MEDLINE (1966-2001), HealthSTAR (1975-2001), Cochrane Library databases, and reference lists of key articles. Recent results of the Women's Health Initiative (WHI) and the Heart and Estrogen/progestin Replacement Study (HERS) are included for reported outcomes.
Study selection and data extraction: We used all published studies of HRT if they contained a comparison group of HRT nonusers and reported data relating to HRT use and clinical outcomes of interest. Studies were excluded if the population was selected according to prior events or presence of conditions associated with higher risks for targeted outcomes.
Data synthesis: Meta-analyses of observational studies indicated summary relative risks (RRs) for coronary heart disease (CHD) incidence and mortality that were significantly reduced among current HRT users only, although risk for incidence was not reduced when only studies that controlled for socioeconomic status were included. The WHI reported increased CHD events (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.02-1.63). Stroke incidence but not mortality was significantly increased among HRT users in the meta-analysis and the WHI. The meta-analysis indicated that risk was significantly elevated for thromboembolic stroke (RR, 1.20; 95% CI, 1.01-1.40) but not subarachnoid or intracerebral stroke. Risk of venous thromboembolism among current HRT users was increased overall (RR, 2.14; 95% CI, 1.64-2.81) and was highest during the first year of use (RR, 3.49; 95% CI, 2.33-5.59) according to a meta-analysis of 12 studies. Protection against osteoporotic fractures is supported by a meta-analysis of 22 estrogen trials, cohort studies, results of the WHI, and trials with bone density outcomes. Current estrogen users have an increased risk of breast cancer that increases with duration of use. Endometrial cancer incidence, but not mortality, is increased with unopposed estrogen use but not with estrogen with progestin. A meta-analysis of 18 observational studies showed a 20% reduction in colon cancer incidence among women who had ever used HRT (RR, 0.80; 95% CI, 0.74-0.86), a finding supported by the WHI. Women symptomatic from menopause had improvement in certain aspects of cognition. Current studies of estrogen and dementia are not definitive. In a cohort study, current HRT users had an age-adjusted RR for cholecystitis of 1.8 (95% CI, 1.6-2.0), increasing to 2.5 (95% CI, 2.0-2.9) after 5 years of use.
Conclusions: Benefits of HRT include prevention of osteoporotic fractures and colorectal cancer, while prevention of dementia is uncertain. Harms include CHD, stroke, thromboembolic events, breast cancer with 5 or more years of use, and cholecystitis.
Comment in
- Relationship between hormone replacement therapy, socioeconomic status, and coronary heart disease.
Grodstein F, Manson JE. Grodstein F, et al. JAMA. 2003 Jan 1;289(1):44-5; author reply 45. doi: 10.1001/jama.289.1.44. JAMA. 2003. PMID: 12503971 No abstract available. - Review: risks and benefits of HRT comparing various sources of evidence.
Colditz G. Colditz G. ACP J Club. 2003 Mar-Apr;138(2):41. ACP J Club. 2003. PMID: 12614126 No abstract available.
Similar articles
- The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
Lemay A. Lemay A. J Obstet Gynaecol Can. 2002 Sep;24(9):711-5. doi: 10.1016/s1701-2163(16)30326-7. J Obstet Gynaecol Can. 2002. PMID: 12360366 - Long-term hormone therapy for perimenopausal and postmenopausal women.
Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Marjoribanks J, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD004143. doi: 10.1002/14651858.CD004143.pub5. Cochrane Database Syst Rev. 2017. PMID: 28093732 Free PMC article. Review. - Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Rossouw JE, et al. JAMA. 2002 Jul 17;288(3):321-33. doi: 10.1001/jama.288.3.321. JAMA. 2002. PMID: 12117397 Clinical Trial. - Is the WHI relevant to HRT started in the perimenopause?
Harman SM, Brinton EA, Clarkson T, Heward CB, Hecht HS, Karas RH, Judelson DR, Naftolin F. Harman SM, et al. Endocrine. 2004 Aug;24(3):195-202. doi: 10.1385/ENDO:24:3:195. Endocrine. 2004. PMID: 15542885 - Hormone replacement therapy and cardioprotection: the end of the tale?
Rosano GM, Vitale C, Silvestri A, Fini M. Rosano GM, et al. Ann N Y Acad Sci. 2003 Nov;997:351-7. doi: 10.1196/annals.1290.038. Ann N Y Acad Sci. 2003. PMID: 14644842 Review.
Cited by
- Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts.
Wang YT, Therriault J, Tissot C, Servaes S, Rahmouni N, Macedo AC, Fernandez-Arias J, Mathotaarachchi SS, Stevenson J, Lussier FZ, Benedet AL, Pascoal TA, Ashton NJ, Zetterberg H, Blennow K, Gauthier S, Rosa-Neto P. Wang YT, et al. Alzheimers Res Ther. 2024 Jul 22;16(1):162. doi: 10.1186/s13195-024-01509-5. Alzheimers Res Ther. 2024. PMID: 39034389 Free PMC article. - The effect of hormone therapy on physiological uptake of the endometrium on [18F]F-FDG PET in postmenopausal women.
Nakamoto R, Yakami M, Nobashi TW, Isoda H, Nakamoto Y. Nakamoto R, et al. Ann Nucl Med. 2024 Sep;38(9):726-733. doi: 10.1007/s12149-024-01941-5. Epub 2024 May 18. Ann Nucl Med. 2024. PMID: 38761311 - Does exogenous hormonal therapy affect the risk of glioma among females: A systematic review and meta-analysis.
Alfuridy G, Alghamdi R, Alkhoshi A, Mahjari A, Alhussein A, Alshehri E, Lary A, Sabbagh A, Alomar S. Alfuridy G, et al. Neurooncol Adv. 2023 Dec 23;6(1):vdad167. doi: 10.1093/noajnl/vdad167. eCollection 2024 Jan-Dec. Neurooncol Adv. 2023. PMID: 38405204 Free PMC article. - Mechanisms of sex differences in Alzheimer's disease.
Lopez-Lee C, Torres ERS, Carling G, Gan L. Lopez-Lee C, et al. Neuron. 2024 Apr 17;112(8):1208-1221. doi: 10.1016/j.neuron.2024.01.024. Epub 2024 Feb 22. Neuron. 2024. PMID: 38402606 Review. - Investigating the synergistic effects of hormone replacement therapy, apolipoprotein E and age on brain health in the UK Biobank.
Ambikairajah A, Khondoker M, Morris E, de Lange AG, Saleh RNM, Minihane AM, Hornberger M. Ambikairajah A, et al. Hum Brain Mapp. 2024 Feb 1;45(2):e26612. doi: 10.1002/hbm.26612. Hum Brain Mapp. 2024. PMID: 38339898 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources